ライフサイエンスコーパス: insulinotropic

1 e, whereas 10 microM forskolin amplified the insulinotropic action of MP.

2 Thus, the insulinotropic actions of pancreatic CRFR1 oppose the ac

3 st, is an exocrine hormone, which has potent insulinotropic actions similar to GLP-1 such as stimulat

4 MIN6 cell line almost completely eliminates insulinotropic activity of M3R.

5 slets, respectively, uniquely attenuated the insulinotropic activity of TAK-875, thus providing funct

6 atocyte growth factor (HGF) is a mitogen and insulinotropic agent for the beta-cell.

7 e physiological importance as a postprandial insulinotropic agent is unknown.

8 oup recently reported the discovery of a new insulinotropic agent, cardiotoxin-I (CTX-I), from the Na

9 ions within the basal range or to additional insulinotropic agents besides GLP mediating the antidiab

10 Extended insulinotropic and antihyperglycemic actions were also e

11 glucagon-like peptide-1 (7-36) amide is both insulinotropic and insulinomimetic and has been suggeste

12 is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimu

13 ate cholecystokinin-8 in the presence of the insulinotropic antidiabetes compounds tolbutamide, glibe

14 The insulinotropic characterization of myricetin was perform

15 Sulfonylurea derivatives exert their insulinotropic effect by binding to the SUR1 subunit of

16 G elicited a protracted glucose-lowering and insulinotropic effect in high fat-fed mice.

17 asma levels, still had an early, short-lived insulinotropic effect in type 2 diabetes.

18 Glp1r-/- mice results from the loss of a non-insulinotropic effect mediated by the Glp1r.

19 -1) in the hyperglycemic state abolished the insulinotropic effect of a physiological dose of GLP-1 a

20 An insulinotropic effect of dairy was not observed.

21 receptor antagonist, we determined that the insulinotropic effect of dibenzazepine was mediated thro

22 The highest insulinotropic effect of exendin-4 was also observed in

23 vention of PKA activation indicated that the insulinotropic effect of genistein is primarily mediated

24 er OATP1B3 functions as a determinant of the insulinotropic effect of glibenclamide on the tissue lev

25 insulin secretion-significantly enhances the insulinotropic effect of glibenclamide without affecting

26 They also show, however, that the insulinotropic effect of individual fatty acids spans a

27 ulin secretion and, instead, antagonizes the insulinotropic effect of Oxo-M and CCh-induced Ca(2+) up

28 e in amidated GLP-1, which can then exert an insulinotropic effect on the remaining beta cells.

29 iabetes by virtue of 1) their powerful acute insulinotropic effect, 2) their ability to exacerbate in

30 ssion by small interfering RNA blocked 43RFa insulinotropic effect, but not the insulinostatic action

31 f the cAMP/PKA signaling cascade to exert an insulinotropic effect, thereby providing a novel role of

32 combination with 10 microM forskolin had no insulinotropic effect.

33 reduced this excursion, due to a synergistic insulinotropic effect.

34 GLP-1 exerts important insulinotropic effects after RYGB and ILM, but the enhan

35 These studies characterize the insulinotropic effects of an early-stage, small molecule

36 T) and hyperglycemic clamp characterized the insulinotropic effects of compounds in vivo.

37 is an important mechanism for mediating the insulinotropic effects of GLP-1.

38 chanistic insight into the recently reported insulinotropic effects of NMDAR antagonists and therefor

39 s a naturally occurring incretin with potent insulinotropic effects the action of which is attenuated

40 n-sensitive subjects: the transcripts of the insulinotropic glucose-dependant peptide (GIP) and of th

41 Glucose-induced secretion of insulinotropic hormone (GIP) and glucagon-like peptide 1

42 the blood glucose-lowering properties of an insulinotropic hormone (glucagon-like peptide-1, also kn

43 peptide-1 (GLP-1) is an intestinally derived insulinotropic hormone currently under investigation for

44 The insulinotropic hormone GLP-1 (glucagon-like peptide-1) i

45 MP, and stimulates the release of the potent insulinotropic hormone GLP-1, resulting in a promising d

46 Here, we show that the insulinotropic hormone glucagon-like peptide (GLP)-1, wh

47 possible therapeutic agent for NIDDM is the insulinotropic hormone glucagon-like peptide 1 (GLP-1).

48 Glucagon-like peptide 1 (GLP-1), an insulinotropic hormone normally synthesised in the intes

49 Glucagon-like peptide 1 (GLP-1) is an insulinotropic hormone released after nutrient ingestion

50 etabolic inactivation of a glucose-dependent insulinotropic hormone, glucagon-like peptide 1 (GLP-1),

51 tivation of the GLP-1R, we characterized the insulinotropic mechanism of BETP.

52 the ERbeta selective agonist WAY200070 as an insulinotropic molecule.

53 To determine whether insulinotropic off-target effects of PEG-IGF-I caused th

54 like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) has been found to be dimini

55 Glucose-dependent insulinotropic peptide (GIP) induces production of inter

56 like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors, can be overexpre

57 like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), can increase the cAMP cont

58 treatments (glucose, KCl, glucose-responsive insulinotropic peptide (GIP), forskolin) that act upon g

59 of cholecystokinin (CCK), glucose-dependent insulinotropic peptide (GIP), glucagon, and neurotensin

60 ll intestine to study the secretion of gluco-insulinotropic peptide (GIP), glucagon-like peptide-1 (G

61 were assayed for insulin, glucose-dependent insulinotropic peptide (GIP), glucose and acetaminophen.

62 lucagon-like peptide 1 and glucose-dependent insulinotropic peptide (the incretin hormones), which in

63 lucagon-like peptide 1 and glucose-dependent insulinotropic peptide and in the regulation of plasma c

64 tylmethylxanthine, and the glucose-dependent insulinotropic peptide inhibited AMPK activity and reduc

65 agon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestina

66 , C-peptide, glucagon, and glucose-dependent insulinotropic peptide were approximately 10-23% lower (

67 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide, and peptide YY (PYY) were measur

68 Fasting total GLP-1, glucose-dependent insulinotropic peptide, and PYY levels were similar betw

69 lucagon-like peptide-1 and glucose-dependent insulinotropic peptide, as well as ghrelin and peptide Y

70 a decrease in metabolic endotoxemia, glucose insulinotropic peptide, glucose intolerance, lipogenesis

71 , glucagon-like peptide 1, glucose-dependent insulinotropic peptide, insulin, glucagon, total amino a

72 lucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are two important incretin

73 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) account for up to 60% o

74 Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are incretins

75 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.

76 t occurred despite similar glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

77 retin effect," mediated by glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

78 influence the magnitude of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

79 Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

80 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are altered in the dise

81 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones t

82 anscript and a decrease in glucose-dependent insulinotropic polypeptide (GIP) gene transcripts were o

83 Glucose-dependent insulinotropic polypeptide (GIP) has been suggested to h

84 milar changes in GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) in response to oral glu

85 and infusion of exogenous glucose-dependent insulinotropic polypeptide (GIP) in the splanchnic regio

86 Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid gast

87 Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid pept

88 Glucose-dependent insulinotropic polypeptide (GIP) is a member of a struct

89 Glucose-dependent insulinotropic polypeptide (GIP) is a physiological insu

90 Since glucose-dependent insulinotropic polypeptide (GIP) is a strong stimulator

91 Glucose-dependent insulinotropic polypeptide (GIP) is an endogenous hormon

92 Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone

93 The glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone

94 Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone

95 Glucose-dependent insulinotropic polypeptide (GIP) is glucagonotropic, and

96 Exploitation of glucose-dependent insulinotropic polypeptide (GIP) is hindered by its shor

97 of the enteroinsular axis, glucose-dependent insulinotropic polypeptide (GIP) may play a critical rol

98 Glucose-dependent insulinotropic polypeptide (GIP) potentiates glucose-sti

99 Glucose-dependent insulinotropic polypeptide (GIP) promotes glucose-depend

100 1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor transduce nutr

101 of its target genes (Pdx1, glucose-dependent insulinotropic polypeptide (GIP) receptor, and pyruvate

102 f the incretin family, the glucose-dependent insulinotropic polypeptide (GIP) receptor.

103 GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) secretions are unaltere

104 se, insulin, glucagon, and glucose-dependent insulinotropic polypeptide (GIP) were analyzed.

105 ike peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured after the

106 ike peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured.

107 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) are secreted from ente

108 loyed to produce PEGylated glucose-dependent insulinotropic polypeptide (GIP), a protein with potenti

109 Glucose-dependent insulinotropic polypeptide (GIP), an incretin hormone se

110 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and cholecystokinin (l

111 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon bind to r

112 ed plasma levels of GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and insulin, and impro

113 cretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), by inhibiting their br

114 A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3-30)NH2, was rece

115 highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-

116 like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), play an important role

117 like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), slow gastric emptying,

118 Glucose-dependent insulinotropic polypeptide (GIP), unlike glucagon-like p

119 ll intestine that produces glucose-dependent insulinotropic polypeptide (GIP), xenin, and potentially

120 n-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

121 nd can be activated by the glucose-dependent insulinotropic polypeptide (GIP).

122 (GCG) receptor (GCGR), and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric i

123 r with the closely related glucose-dependent insulinotropic polypeptide (GIPR) and glucagon (GCGR) re

124 and decreased ghrelin and glucose-dependent insulinotropic polypeptide (P < 0.05).

125 Glucose-dependent insulinotropic polypeptide [also known as gastric inhibi

126 like peptide 1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]), whereas metformin may

127 ponses of intact GLP-1 and glucose-dependent insulinotropic polypeptide and lowered glucose responses

128 e, insulin, C-peptide, and glucose-dependent insulinotropic polypeptide concentrations were significa

129 lucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide have been postulated to play

130 nction (P < 0.01), and reductions in glucose-insulinotropic polypeptide levels (P < 0.001), glucagon

131 e same PPRE within the rat glucose-dependent insulinotropic polypeptide receptor (GIP-R) promoter seq

132 essing a dominant-negative glucose-dependent insulinotropic polypeptide receptor (GIPR(dn)) reveal pr

133 To study active GLP-1, glucose-dependent insulinotropic polypeptide receptor (Gipr)-deficient mic

134 001), and no difference in glucose-dependent insulinotropic polypeptide responses compared with sham-

135 ction of glucagon-like peptide-1 and glucose-insulinotropic polypeptide were assessed during a meal t

136 peptide-1 (GLP-1) and GIP (glucose-dependent insulinotropic polypeptide), respectively.

137 ral gut hormones (insulin, glucose-dependent insulinotropic polypeptide, and glucagon-like peptide 1)

138 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, increases in proportion to m

139 y and beta-cell function and reduced glucose-insulinotropic polypeptide, leptin, and glucagon product

140 apart from GLP-1, such as glucose-dependent insulinotropic polypeptide, stromal-derived factor-1alph

141 d postprandial response of glucose-dependent insulinotropic polypeptide.

142 lucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.

143 ns of endogenous GLP-1 and glucose-dependent insulinotropic polypeptide.

144 Again, lard oil exhibited greater insulinotropic potency.

145 tion of PI3Kgamma blunted the exocytotic and insulinotropic response to GIP receptor activation, wher

146 Insulinotropic responses in clonal beta-cells were simil

147 number and area, as well beta-cell area and insulinotropic responsiveness, were dramatically improve

148 ionally linked to a beta-arrestin 2-mediated insulinotropic signaling axis.

149 eceptor mobilization of cAMP is the critical insulinotropic signaling event.